FC III. Prostacyclin and milrinone by aerosolization improve pulmonary hemodynamics in newborn lambs with experimental pulmonary hypertension. J Appl Physiol 109: 677-684, 2010. First published July 8, 2010 doi:10.1152/japplphysiol.01082.2009.-Aerosolized prostacyclin (PGI 2) produces selective pulmonary vasodilation in patients with pulmonary hypertension (PH). The response to PGI2 may be increased by phosphodiesterase type 3 inhibitors such as milrinone. We studied the dose response effects of aerosolized PGI 2 and aerosolized milrinone both alone and in combination on pulmonary and systemic hemodynamics in newborn lambs with N -nitro-L-arginine methyl ester (L-NAME)-induced PH. We hypothesized that coaerosolization of PGI2 with milrinone would additively decrease pulmonary vascular resistance (PVR), prolong the duration of action of PGI 2, and selectively dilate the pulmonary vasculature. Near-term lambs were delivered by C-section and instrumented and PH was induced by L-NAME (bolus 25 mg/kg; infusion 10 mg · kg Ϫ1 · h
) and indomethacin. In the first set of experiments, PGI 2 was aerosolized at random doses of 2, 20, 100, 200, 500, and 1,000 ng · kg Ϫ1 · min Ϫ1 followed by milrinone at doses of 0.1, 1, and 10 g · kg Ϫ1 · min Ϫ1 over 10 min. In the second set of experiments, milrinone at 1 g · kg Ϫ1 · min Ϫ1 was aerosolized in combination with PGI 2 at doses of 20, 100, and 200 ng · kg Ϫ1 · min Ϫ1 over 10 min. Pulmonary arterial pressures (PAP) and PVR decreased significantly with increasing doses of aerosolized PGI 2 and milrinone. The combination of PGI 2 and milrinone significantly reduced PAP and PVR more than either of the drugs aerosolized alone. Addition of milrinone significantly increased the duration of action of PGI 2. When aerosolized independently, PGI2 and milrinone selectively dilated the pulmonary vasculature but the combination did not. Milrinone enhances the vasodilatory effects of PGI 2 on the pulmonary vasculature but caution must be exercised regarding systemic hypotension.
pulmonary vascular resistance; pulmonary arterial pressure; pulmonary blood flow; persistent pulmonary hypertension of the newborn; systemic blood pressure PULMONARY HYPERTENSION (PH) of any etiology if untreated is a potentially fatal condition in children and adults (3) . Nitric oxide (NO) and prostacyclin (PGI 2 ) are used extensively as vasodilators in the short-term and long-term management of primary and secondary PH in children and adults (19, 32, (35) (36) (37) . Lack of selectivity of intravenous PGI 2 can lead to generalized vasodilation of systemic and pulmonary vessels, resulting in systemic hypotension. Persistent pulmonary hypertension of the newborn (PPHN) is a serious disorder of term and near-term infants with significant morbidity and mortality (33) . Although inhaled nitric oxide (iNO) is commonly used to treat refractory cases of PPHN, 40% of infants do not respond to iNO (25) . Prostacyclin analogs have been used in these infants with PPHN (4, 28) and found to be effective in infants not responding to iNO (13) . PGI 2 increases cAMP by stimulating the enzyme adenylate cyclase within the vascular smooth muscle resulting in vasodilatation (17) . Systemic hypotension and nonselective increase in perfusion of both ventilated and nonventilated units of the lung are particularly problematic with intravenously administered vasodilators such as PGI 2 (22) . Aerosolized PGI 2 selectively dilates the pulmonary circulation and redistributes pulmonary blood flow away from nonventilated regions of the lung (21, 31) . Aerosolized PGI 2 has been shown to be at least as effective as iNO in decreasing PH in some animals and humans (9, 35) . Because of its short biological half-life of 2-3 min at physiological pH (17) , its vasodilatory effect on the lung vasculature wears off in Ͻ30 min after termination of nebulization (19) .
Milrinone increases cAMP levels by inhibiting the enzyme phosphodiesterase type 3 (PDE 3) in cardiac and vascular smooth muscle. Milrinone is a positive inotrope and vasodilator and has been a valuable drug in the management of patients with congestive cardiac failure, shock, and following cardiac surgery (2, 6, 11, 23, 27) . By increasing cAMP levels through different mechanisms, the combination of PGI 2 and milrinone may enhance the relaxation of the pulmonary vascular bed and also prolong the vasorelaxant effects. We showed previously that milrinone enhances the relaxation to PGI 2 and iloprost in pulmonary arteries isolated from lambs with PPHN (14) . We also demonstrated that intravenously administered milrinone potentiates the vasodilatory effects of intratracheally instilled PGI 2 in newborn lambs with ductal ligation-induced PPHN (24) .
Although there are reports of aerosolized PGI 2 being used anecdotally in human newborn infants (1, 4, 13) , systematic studies on the dose response effect of aerosolized PGI 2 in infants and children with PH is lacking. Unlike aerosolized milrinone, intravenous milrinone has been extensively studied in patients with PH associated with cardiac failure (2) . Very few studies (11, 26) have addressed the hemodynamic effects of aerosolized milrinone in adult patients with PH, but none in the pediatric age group. As combining PGI 2 and milrinone enhances relaxation of PAs (14) and also reduces pulmonary arterial pressure (PAP) in an in vivo model (24) , coaerosolization may offer potential benefits. We studied the dose response of aerosolized PGI 2 and milrinone on pulmonary and systemic hemodynamics in newborn lambs with experimental PH. We hypothesized that coaerosolization of PGI 2 with milrinone would enhance the decrease in pulmonary vascular resistance (PVR), prolong the duration of action, and maintain the selec-tivity of the effect on the pulmonary vasculature. Thus we studied the agents in combination as well.
METHODS
The study was approved by the IACUC of the University at Buffalo. Sheep were purchased from Swartz family farm (Attica, NY).
Surgical preparation of the lamb. Time-dated pregnant sheep at 139 days gestation (term 145 days) were brought to the lab animal facility 24 -72 h before surgery. After intravenous Pentothal (750 mg), the ewe was intubated and ventilated under general anesthesia (1-2% isoflurane). After partial exteriorization of the fetal head and neck via C-section, the carotid artery and jugular vein were catheterized. A left lateral thoracotomy was then performed in the fourth intercostal space on the fetus, and the pericardium was exposed. Ductus arteriosus was ligated to minimize variability in pulmonary blood flow (PBF) and PAP resulting from a dynamic shunt due to PH and/or administration of PGI 2 or milrinone. An ultrasonic flow transducer (Transonics Systems, Ithaca, NY) was placed around the main pulmonary artery (PA) for measurement of pulmonary blood flow (PBF). Catheters were placed in the main PA and in the left atrium (LA) to measure PA and LA pressures, respectively. The lamb was then intubated with a cuffed endotracheal tube. To induce and maintain pulmonary hypertension by antagonizing the vasodilatory effects of endogenous nitric oxide (NO) and PGI 2, N-nitro-L-arginine methyl ester (L-NAME) was administered at a dose of 25 mg/kg by a slow intravenous push over 2-3 min just before delivery of the lamb and freshly prepared indomethacin at a dose of 2 mg/kg was administered by slow intravenous push within 5 min after birth. Lambs were maintained on L-NAME infusion at 10 mg · kg Ϫ1 · h Ϫ1 postdelivery. The lambs were delivered with an open chest and catheters and transducer in situ.
The lambs were placed under a servo controlled infant warmer to maintain rectal temperature of 39°C and weighed immediately. Lambs were covered in a plastic bag to prevent heat loss. Ventilation was initiated with a time cycled pressure controlled Sechrist ventilator (Sechrist Industries, Anaheim, CA) at a rate of 60 breaths/min, PIP set to achieve adequate chest movement (22-26 cmH 20) , PEEP of 4 -5 cmH20, I-time of 33% [I:E ϭ 1:2] and FIO 2 of 1. Intravenous fluids (10% dextrose ϩ NaCl: 25 meq/l ϩ KCl: 20 meq/l ϩ NaHCO3: 10 meq/l) were administered continuously at 100 ml · kg Ϫ1 · day Ϫ1 . Blood pressure, heart rate, temperature, and oxygen saturation were monitored continuously and arterial blood gases were obtained before and after aerosolization doses and as needed throughout the study. The lambs were well sedated with fentanyl administered as an infusion (3 g·kg Ϫ1 ·h Ϫ1 ) with additional boluses of 5 g/kg as needed. Lambs with persistent increased activity despite adequate sedation were paralyzed with pancuronium bromide (0.1 mg/kg every 3-4 h as needed). Lambs received normal saline or whole blood for low mean blood pressure of Ͻ35 mmHg and sodium bicarbonate for base deficit of Ն8 meq/l. Blood gases were done frequently during stabilization to maintain Pa CO2 35-55 mmHg and pH 7.35-7.45. Inspired oxygen was maintained at 100% throughout the study period. All catheters were connected to a physiological recorder (Gould Instrument Systems, Valley View, OH) for monitoring of systemic blood pressure (SBP), PAP, and LA pressure (LAP; mmHg). The flow probe was connected to a flow meter (Transonic Systems) for monitoring of PBF (ml/min). Pulmonary vascular resistance (PVR) was calculated using the standard formula (PAP Ϫ LAP)/PBF and corrected for body weight and expressed as millimeters Hg per milliliter per kilogram per minute. Hemodynamic data were also obtained from normal newborn lambs at similar gestational age (historic controls) instrumented for other reasons and compared them with PH lambs. Duration of action of aerosolized PGI 2 with and without milrinone was defined as the time elapsed since the administration of the drugs for the PAP to decrease and then come back up to the preadministration baseline. Selectivity of the drug to the pulmonary vasculature was assessed by calculating the mean PAP-to-SBP ratio for the doses studied.
Delivery of prostacyclin and milrinone. The animals were allowed to stabilize on L-NAME infusion on 100% oxygen and documented to have pulmonary hypertension after birth (mean PAP Ͼ 50 mmHg). The first dose of the aerosolized drug was administered at 2-3 h after birth. The drugs were administered with the Aeroneb nebulizer system (Aeroneb Pro, Aerogen Mountain View, CA) placed in the inspiratory limb of a humidified ventilatory circuit connecting the ventilator to an endotracheal tube. The aerosol generator produces a fine particle, low-velocity aerosol and does not heat the medication during nebulization. The mass median aerodynamic diameter of the particles delivered by this nebulizer is 2.1 m (SD Ϯ 2.2) with the fine particle fraction (Ͻ5 m) of 83% and residual volume of 0.3 ml (5). PGI2 (Sigma Chemicals, St. Louis, MO) and milrinone (Baxter Healthcare, Deerfield, IL) solutions were freshly prepared before the start of each experiment. PGI2 solution was prepared using glycine buffer (pH 10.4) and milrinone using normal saline. The response for PGI2 was studied at doses of 2, 20, 100, 200, 500, and 1,000 ng · kg Ϫ1 · min Ϫ1 aerosolized in random order over 10 min in five newborn lambs. The response to milrinone was studied in sequentially increasing doses of 0.1, 1, and 10 g·kg Ϫ1 · min Ϫ1 aerosolized over 10 min in the same lambs following PGI2. Aerosolization of both the drugs in combination was performed in a second set of lambs (n ϭ 5) after analysis of dose response results from the earlier experiments. In the second set of experiments, PGI2 (20, 100, and 200 ng · kg Ϫ1 · min Ϫ1 ) and milrinone (1 g·kg Ϫ1 · min Ϫ1 ) were administered alone and in combination (PGI2 20 ϩ milrinone 1 g·kg Ϫ1 · min Ϫ1 ; PGI2 100 ϩ milrinone 1 g·kg Ϫ1 · min Ϫ1 ; PGI2 200 ϩ milrinone 1 g·kg Ϫ1 · min Ϫ1 ) and again aerosolized over 10 min via the aeroneb. PGI2 doses were administered at random followed by milrinone at 1 g·kg Ϫ1 · min Ϫ1 . The combination doses were then administered in sequentially increasing doses of 20, 100, and 200 of PGI2 with milrinone. The nebulized volume in all the experiments was 5 ml, which took about 10 min to nebulize with a residual volume of Ͻ0.3 ml. Blood gases were done pre-and postnebulization of the drugs. Fixed ventilator settings were maintained during the aerosolization period. A time interval of at least 30 min was maintained between doses to allow for the PAP to revert back to the prenebulization baseline.
We used the integrated pharmacokinetic/pharmacodynamic (PK/ PD) approach to study the relationships between dose and effect in a statistical model accounting for variability to a given dose and among various doses of PGI2 and milrinone. Mathematically the graded concentration-effect relationship in a physiological system is represented by the sigmoidal E max equation: E ϭ Emax ϫ C s /(C s ϩ EC s 50), where Emax is the maximum effect, C is the concentration (dose), EC50 is the concentration of the drug that induces a response halfway between the baseline and maximum effect and s is the Hill coefficient (18) . All data are expressed as mean Ϯ SD with n representing the number of animals. The concentration-effect relationship Emax model was fitted by nonlinear mixed model procedure in SAS. The comparisons between drugs and doses were performed by mixed model with drug and doses as fixed effects and subject as a random effect. Statistical analysis was performed using SAS (Cary, NC). Differences among groups were analyzed by ANOVA and Student's t-test. A P value of Ͻ0.05 was considered significant.
RESULTS
L-NAME plus indomethacin produced significant PH in newborn lambs (Table 1) . The values in normal newborn lambs for the same hemodynamic parameters at similar gestational age are also shown in Table 1 . Hemodynamic measurements were made following stabilization 2-3 h after birth in control lambs and in lambs with PH. Mean PAP and PVR were significantly higher and PBF significantly lower in lambs with PH compared with the control group (Table 1) .
Aerosolized PGI 2 . PAP decreased significantly with increasing doses of PGI 2 (P ϭ 0.007; Table 2 ). The mean decrease in PAP after administration of PGI 2 was significantly related to the increasing doses of PGI 2 (Fig. 1A) . The observed maximal decrease in PAP was 19.2 Ϯ 4.4 mmHg (30 Ϯ 6%). There was no significant correlation between pulmonary blood flow and increasing doses of PGI 2 ( Fig. 1B; Table 2 ). Increasing doses of aerosolized PGI 2 significantly reduced PVR (P ϭ 0.008; Table 2 ). The mean decrease in PVR was significantly related to increasing PGI 2 doses (Fig. 1C) . PAP-to-SBP ratio, a measure of selectivity to pulmonary vasculature decreased with increasing doses of PGI 2 (P ϭ 0.05; Fig. 3A ), suggesting that aerosolized PGI 2 was selective to the pulmonary vasculature.
Aerosolized milrinone. There was a significant decrease in PAP with increasing doses of milrinone (P ϭ 0.002; Table 2 ). The mean change in PAP was significantly related to the increasing doses of milrinone ( Fig. 2A) . The observed maximal decrease in PAP was 7.6 Ϯ 0.9 mmHg (14 Ϯ 1%). There was no significant correlation between pulmonary blood flow and increasing doses of milrinone ( Fig. 2B ; Table 2 ). Aerosolized milrinone significantly reduced PVR (Table 2 ; P ϭ 0.002). The mean change in PVR was significantly related to the increasing concentration of milrinone doses (Fig. 2C) , which was close to the observed maximal decrease in PVR of Ϫ0.30 Ϯ 0.03 mmHg·ml Ϫ1 ·kg Ϫ1 ·min Ϫ1 (Ϫ30 Ϯ 4%). PAP-to-SBP ratio, a measure of pulmonary selectivity decreased with increasing doses of milrinone (P ϭ 0.02; Fig. 3B ), suggesting that aerosolized milrinone was selective to the pulmonary vasculature. Although there was a clinical improvement in oxygenation, there was no significant increase in arterial PO 2 postnebulization of PGI 2 or milrinone (Table 4) .
Combination studies. In the second set of experiments, PGI 2 at doses of 20, 100 and 200 ng·kg Ϫ1 ·min Ϫ1 and milrinone at 1 g·kg Ϫ1 ·min Ϫ1 when administered separately significantly reduced PAP (Table 3 ; P ϭ 0.008). Aerosolization of PGI 2 and milrinone together significantly reduced PAP (Table 3 ; Fig. 4A ; P ϭ 0.01) compared with either of the drugs alone. Milrinone by itself did not increase PBF but in combination with PGI 2 significantly increased PBF (Table 3 ; Fig. 4B ; P ϭ 0.04). Combined aerosolization of PGI 2 and milrinone significantly reduced PVR ( Fig. 5 ; P ϭ 0.003) compared with aerosolization of either of the drug alone ( Data represent mean Ϯ SD in 5 newborn lambs with pulmonary hypertension. *PAP: PGI2, Post vs. Pre: P ϭ 0.007; Milrinone, Post vs. Pre: P ϭ 0.002. *PVR: PGI2, Post vs. Pre: P ϭ 0.008; Milrinone, Post vs. Pre: P ϭ 0.002. Data set of all doses of the given drug taken as a group for analysis); mixed modeling procedure. Measured parameters, PAP, PBF, and SBP; Calculated parameters, PVR.
cantly prolongs the duration of action of PGI 2 at the doses studied (P Ͻ 0.05; ANOVA). There was no significant decrease in the PAP-to-SBP ratio following coaerosolization of PGI 2 and milrinone, suggesting that the combination was not selective to the pulmonary vasculature (Fig. 3C) . Combination of PGI 2 and milrinone did not produce any significant difference in ABG parameters such as Pa O 2 , pH, and Pa CO2 following aerosolization.
DISCUSSION
To our knowledge, this is the first study evaluating the dose response to aerosolized PGI 2 and milrinone in an animal model of experimental PH. We have shown that aerosolized PGI 2 decreases PAP and PVR in a dose-dependent manner in newborn lambs with PH. Aerosolized PGI 2 has been shown in a number of human studies to be beneficial in patients with adult respiratory distress syndrome (ARDS) (32), primary and secondary PH (16) , and right ventricular dysfunction (10) . Similar to our study, human studies have found a decrease in PAP and PVR with inhaled PGI 2 at doses of 50 to 100 ng·kg Ϫ1 ·min
Ϫ1
in cardiac surgical patients with elevated PVR (9, 11). Aerosolized PGI 2 (85 ng·kg Ϫ1 ·min
) reduced pulmonary pressures and improved right ventricular stroke volume in patients with PH undergoing cardiac surgery (8) . This being an animal model, we were able to test a wide range of aerosolized PGI 2 from 2 to 1,000 ng·kg Ϫ1 ·min Ϫ1 . The EC 50 for the doses tested was 170 (Ϯ53) ng·kg Ϫ1 ·min
, which was comparable to the clinical therapeutic range reported in various studies.
Despite the high doses, aerosolized PGI 2 was selective to the pulmonary vasculature as determined by PAP-to-SBP ratio and a lack of significant decrease in SBP. Inhaled PGI 2 in hypoxemic patients with ARDS at doses up to 50 ng ·kg Ϫ1 ·min
was found to be a selective pulmonary vasodilator with no demonstrable effect on SBP (30) . Selectivity of aerosolized PGI 2 to the pulmonary vasculature has been demonstrated in several studies to be comparable to that of iNO (9, 32) and is probably due to rapid inactivation at physiological pH. But PGI 2 when reconstituted in a specific diluent has a pH of 10.4 to 10.8 and is increasingly unstable at lower pH. The effects of high pH when administered as an aerosol over a longer time period are not well studied. However, it has been used in the treatment of PH in adults with minimal side effects and inhalation of PGI 2 over an 8-h period in healthy lambs did not produce major side effects or acute pulmonary toxicity (7).
Aerosolization with increasing doses of milrinone produced a dose-dependent decrease in PAP and PVR in newborn lambs with PH. The fall in PAP was selective to the pulmonary vasculature. Two studies have addressed the hemodynamic effects of aerosolized milrinone in adult patients with PH (11, 26) . However, no studies have addressed the role of aerosolized milrinone in infants and children. In adult patients with PH following cardiac surgery, milrinone aerosolization at two different concentrations of 0.5 and 1 mg/ml produced a selective reduction in PVR of 9 and 20% respectively (11) . The maximal dose of milrinone in this clinical study was ϳ30 -40% of the maximal dose used to our study. Selective vasodilation of the pulmonary vasculature was also noted during evaluation of heart transplant candidates with chronic heart failure (26) . Aerosolized milrinone but not intravenous milrinone was a selective pulmonary vasodilator in a rat model of congestive heart failure (12) . Repeated milrinone inhalations in 20-min intervals also caused a stable reduction in PAP and lung edema in this rat model, suggesting it may offer an effective pulmonary selective strategy for treatment of congestive heart failure in humans (12) . While PAP and PVR were significantly lower when PGI 2 and milrinone were aerosolized separately in our experiments, this was not accompanied by a corresponding increase in PBF, probably secondary to ductal ligation and prevention of left to right shunt.
In the second set of experiments, PGI 2 (20, 100, and 200 ng·kg Ϫ1 ·min Ϫ1 ) and milrinone (1 g·kg Ϫ1 ·min Ϫ1 ) produced a significant reduction in PAP and PVR when aerosolized independently in these lambs with PH. Aerosolization of milrinone with any of the three PGI 2 doses resulted in an additional decrease in PAP and PVR greater than seen with either drug alone, suggesting that the drugs may act in synergy. PGI 2 combined with milrinone produced an additional reduction in PVR of 8.3-9.9% across doses. The only other study of combined aerosolization was performed in adults with postoperative cardiac surgery patients with PH using one dose of each agent (11) . In this study, aerosolized PGI 2 with milrinone produced a reduction in PVR by an additional 8% compared with PGI 2 alone. This is the first report of the results of aerosolization of milrinone combined with varying doses of aerosolized PGI 2 . Our data suggests that coaerosolization with a PDE3 inhibitor enhances the response in the pulmonary vascular bed across most of the clinically relevant doses of PGI 2 (20 - 
). The addition of 1 g·kg Ϫ1 ·min Ϫ1 of milrinone decreased the EC 50 of PGI 2 from 170 (Ϯ53) to 40 (Ϯ16) ng·kg Ϫ1 ·min Ϫ1 , suggesting that a lower dose of PGI 2 could be used when aerosolized with milrinone. Aerosolized milrinone prolonged the duration of reduction in PAP to PGI 2 . Combination therapy seems to achieve both augmentation and prolongation of PGI 2 action on the pulmonary vascular bed. Similar enhancement of duration and degree of pulmonary vasodilation with a combination of inhaled milrinone and PGI 2 has been observed in cardiac postoperative patients with PH following discontinuation of inhalation (11) . Amplification of pulmonary vasodilator response following administration of PDE inhibitors with PGI 2 , suggests that administering these drugs by aerosolization may be advantageous in the treatment of PH.
Aerosolization is said to deliver the drug to the site of desired action, thereby improving systemic oxygenation and minimizing systemic side effects. However, the effect on systemic oxygenation following PGI 2 and milrinone was not Fig. 3 . PAP-to-SBP ratio in newborn lambs with PH. Y-axis represents the ratio of PAP to SBP (raw data) with increasing doses of PGI2 (placebo, 2, 20, 100, 200, 500, and 1,000 ng · kg Ϫ1 · min
; A), milrinone (B), and combination of PGI2 and milrinone (C). Data represent mean (ϮSE) from 5 lambs. There was no difference in the ratio pre-and postaerosolization, suggesting that the combination was not selective to the pulmonary vasculature. The ratio, a measure of selectivity to pulmonary vasculature decreased with increasing doses of PGI2 (A; *P ϭ 0.05) and milrinone (B; †P ϭ 0.02; mixed modeling). The combination of PGI2 and milrinone was not selective to the pulmonary vasculature.
one of uniform and significant improvement across all doses. This could be related to intracardiac shunting of blood secondary to significant pulmonary hypertension and also to intrapulmonary shunting in an instrumented, sick postoperative newborn lamb. PGI 2 and milrinone when aerosolized independently were selective to the pulmonary vasculature as indicated by PAP-to-SBP ratio. However, the combination was not selective by the same parameter in our study. Two studies that have addressed this issue have demonstrated selectivity of milrinone to the pulmonary vasculature (11, 26) . The interaction between PGI 2 and milrinone is influenced by their differing half-lives. PGI 2 has a biological half-life of 2-3 min (17) and a duration of action of Ͻ30 min following nebulization in human studies (19) . Pharmacokinetic data on milrinone suggests that the half-life of intravenous milrinone varies from 1.86 to 3.15 h (15, 23), but there is a paucity of data on half-life of aerosolized milrinone. Although it is difficult to extrapolate intravenous half-life following an aerosolized dose, it is still reasonable to believe that the duration of action of milrinone is much longer than PGI 2 . Aerosolized milrinone selectively dilated the pulmonary vasculature for a relatively short time (10 -30 min) during evaluation of heart transplant candidates with elevated pulmonary arterial pressures (26) . Inhaled milrinone induced a dose-dependent selective pulmonary vasodilation in postop cardiac patients with PH (11) and the effects of incremental concentrations on central hemodynamics were noted 20 min following inhalations. Measurements in a rat model of congestive heart failure were also made in 20-min intervals following repeated milrinone inhalations (12) . Current studies recorded hemodynamic parameters for up to 30 min with inhaled milrinone. There is paucity of data on not only the duration of effect of a single dose of aerosolized milrinone but also on when a repeat dose needs to be administered. In our study, combination doses were administered with at least 30-min interval between doses, once PAP reverted back to prenebulization value. Thirty minutes between doses is probably adequate for PGI 2 , but may not be for milrinone. Milrinone has the potential to cause systemic hypotension especially when administered frequently (i.e., 30-min intervals) by aerosolized route, in view of its longer half-life, although this has not been a concern with other studies. It is possible that sequential administration of milrinone might have led to tissue accumulation of the drug and its subsequent crossing into systemic circulation, leading to systemic hypotension. This might explain the nonselectivity of PAP-to-SBP ratio in combination experiments. This is one of the limitations of the study. In addition, the calculated PAP-to-SBP ratio was used as a surrogate to PVR-to-SVR ratio for pulmonary selectivity. The lack of data on cardiac output and hence of systemic vascular resistance makes it difficult to comment on vascular selectivity in our experiments. This was a conscious decision on our part not to perform double thoracotomies (to measure cardiac output) in these sick newborn lambs. These issues may explain the nonselectivity of the combination of milrinone and PGI 2 or might also represent a significant limitation of the study. The pharmacologically induced PH in newborn lambs is not the same as the clinical condition of PH in infants and children. We induced PH with a single dose of indomethacin, which has a longer half-life and a continuous infusion of L-NAME, a NOS inhibitor. The rationale for using both of these agents was to block endogenous PGI 2 and NO, the two major pathways contributing to pulmonary vasodilatation, resulting in the physiological fall in PVR that occurs soon after birth. Indomethacin, by blocking endogenous PGI 2 , also allowed us to study more accurately the effects of exogenously administered PGI 2 and milrinone on pulmonary hemodynamics. Blocking endogenous NO and PGI 2 production induced severe PH secondary to acute vasoconstriction in newborn lambs. Moreover the features that often complicate the clinical condition of PH such as parenchymal lung disease and vascular remodeling were absent in this model. Vasoconstrictors such as thrombaxane and endothelin produced by the vascular endothelium along with the structural remodeling of the pulmonary vasculature contribute to PH in infants and children. However, a decrease in response to NO may also contribute to abnormal vasoreactivity and excessive muscularization of the pulmonary vessels in PH (29) . It is possible for our results to be affected by the interaction of the cAMP and cGMP systems via the PDE cross talk. As neither cGMP nor cAMP levels were measured either in the blood or in the pulmonary arteries, we can only speculate at this point regarding cross talk between the two signal transduction pathways. Sildenafil, a PDE5 inhibitor has been shown to exert anitimitogenic action by activation of PKA by inhibition of PDE3 (20) . In the absence of increasing cGMP by NOS inhibition in our model, it is unlikely for any significant PDE3 inhibition to have taken place; although a negative feedback (low cGMP potentiating PDE3) cannot be ruled out. However, in experiments involving milrinone and PGI 2 with milrinone, this effect on PDE3 should have been abolished. Increasing cAMP from PGI 2 alone might also have a modulating effect on the cGMP system as reported in literature (34) . In this acute model of PH lasting for several hours, there may be less time for smooth muscle proliferation and vascular remodeling to occur. Moreover newborn vasculature may behave differently relative to adult vasculature, which may go on to develop either atherosclerosis or primary PH. Although, the clinical responses were along expected lines in our model, cross talk among PDEs needs to be studied further.
Despite the above mentioned limitations, the study generates the pharmacodynamic data of exogenously administered PGI 2 and milrinone by aerosolized route in newborn lambs with PH. Augmenting the cAMP pathway with combination therapy is relatively unexplored in infants and children compared with agents that act on the cGMP pathway and this may have clinical implications. The study demonstrated the effectiveness of these agents in the newborn lung vasculature and the potential for exploring these agents via aerosolization. We found that aerosolized PGI 2 and aerosolized milrinone significantly reduce PVR in a dose-dependent manner in this model. PGI 2 and milrinone had synergistic effects on the pulmonary circulation when aerosolized in combination. Coaerosolization of milrinone with PGI 2 enhanced and prolonged the duration of action of PGI 2 . Future studies evaluating the role of coaero- 
